ORLANDO, FL — July 9, 2026 — NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, today announced it has formally ceased all operations within the cannabis and CBD industries. The Company will not be loading CBD into exosomes. Moving forward, the Company is entirely committed to the wellness and healthcare sectors.
About NexTel Medical Corp.
NexTel Medical Corp. (OTCPK: MAJI) is a pioneering biotechnology leader at the forefront of exosome research, clinical diagnostics, and wellness accessibility. The Company specializes in developing proprietary, next-generation, exosome-based delivery systems and non-invasive screening tools designed to revolutionize both therapeutic and diagnostic modalities.
NexTel's fully integrated ecosystem spans four core strategic divisions, bridging the gap between complex biotech innovation and scalable market delivery:
- Maxasome Health Check: Proprietary non-invasive liquid biopsy diagnostics utilizing the NANOG DNA assay for universal early-stage cancer screening.
- Maxasome™ PLUS: Next-generation, high-bioavailability wellness therapeutics powered by 100% pure exosomal delivery systems.
- JumpstartRx (www.Jumpstartrx.com): A direct-to-consumer telehealth platform tailored for enterprise employers, large organizations, and affinity groups, providing streamlined, cost-effective access to essential wellness medications.
- NueVistraMed (www.NuevistraMed.com): An institutional ecosystem providing over 1,850 digital and physical medical clinics with collective buying power, wellness pharmaceuticals, patent-pending delivery systems, and a strategic manufacturing partnership with a prominent 503B compounding facility for accessible testosterone therapies.
Serving a nationwide clinical network, NexTel is uniquely positioned to accelerate the commercial launch of its product pipeline while driving immediate revenue growth and long-term shareholder value.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. NexTel Medical Corp's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of NexTel Medical Corp., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
NexTel
Medical Corp.
www.nextelmedical.com
X: @NexTelMedical